Oluyemi Okupe Sells 85,000 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 85,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $60.20, for a total transaction of $5,117,000.00. Following the completion of the sale, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $4,227,966.40. This trade represents a 54.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.74, for a total transaction of $1,361,740.16.
• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $55.35, for a total transaction of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $43.69, for a total value of $505,973.89.
• On Monday, July 14th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $47.70, for a total value of $552,413.70.
• On Monday, July 7th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $46.67, for a total value of $540,485.27.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $56.27 on Thursday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a fifty-two week low of $16.05 and a fifty-two week high of $72.98. The firm has a market capitalization of $12.72 billion, a PE ratio of 70.33, a price-to-earnings-growth ratio of 3.83 and a beta of 2.25. The stock’s 50-day simple moving average is $51.55 and its 200-day simple moving average is $46.86.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the business posted $0.06 EPS. Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Virtus Advisers LLC acquired a new position in Hims & Hers Health during the 2nd quarter worth approximately $26,000. Quaker Wealth Management LLC acquired a new position in Hims & Hers Health during the second quarter worth $29,000. Bessemer Group Inc. grew its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the period. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the first quarter worth $30,000. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in shares of Hims & Hers Health by 408.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after purchasing an additional 600 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on HIMS shares. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.